Phibro Animal Health Corporation's stock soared 10.68% during the trading session, driven by the company's release of second-quarter financial results that significantly exceeded market expectations.

The animal health firm reported adjusted earnings per share of $0.87 for the quarter, beating the consensus estimate of $0.67 by 29.85%. Quarterly sales reached $373.9 million, surpassing estimates by 5.14% and representing a 20.89% increase compared to the same period last year. Adjusted EBITDA rose 41% to $68.1 million.

Furthermore, Phibro Animal Health raised its financial guidance for fiscal year 2026, now projecting net sales between $1.45 billion and $1.50 billion and adjusted EBITDA between $245 million and $255 million. The strong performance was attributed to faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings across key markets.